The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Oncology Precision Medicine Market Become By 2030 Compared To 2026?
The oncology precision medicine market size has seen significant expansion in recent years. It is projected to grow from $125.14 billion in 2025 to $141.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. The growth observed in the historical period was driven by factors such as the limited availability of genomic testing, the reliance on standard chemotherapy protocols, the increasing prevalence of cancer, the early development of molecular diagnostics, and the adoption of hospital-based oncology research programs.
The oncology precision medicine market is anticipated to undergo significant expansion in the next few years. It is forecasted to achieve a size of **$226.55 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%**. The growth expected within this period can be attributed to advancements in CAR-T and gene therapies, an increase in targeted kinase and immune checkpoint inhibitors, rising investments in precision oncology research, the integration of bioinformatics and AI in clinical decision-making, and the expansion of biomarker-guided clinical trials. Prominent trends for the forecast period include a rising adoption of personalized cancer therapies, increasing use of companion diagnostics and molecular diagnostics, growth in liquid biopsy and next-generation sequencing assays, expansion of targeted therapeutics and monoclonal antibodies, and an increasing focus on biomarker-based patient stratification.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp
What Market Drivers Are Helping Shape The Oncology Precision Medicine Market Expansion?
The increasing occurrence of cancer is projected to fuel the expansion of the oncology precision medicine market moving ahead. Cancer is characterized by the uncontrolled proliferation of abnormal cells, which can disseminate throughout the body and interfere with regular physiological processes. This rise in cancer prevalence is attributed to aging populations, where extended lifespans contribute to the buildup of deoxyribonucleic acid (DNA) mutations, impaired cellular repair mechanisms, persistent low-grade inflammation (chronic inflammaging), reduced immune oversight, and tissue surroundings that increasingly foster tumor development. Oncology precision medicine offers benefits for cancer treatment by delivering individualized therapies tailored to the specific genetic profile of each tumor, thereby enhancing efficacy and mitigating adverse reactions. For example, in February 2024, data from the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicated that the approximately 20 million new cancer cases in 2022 are anticipated to surge by 77% to exceed 35 million cases by 2050. Consequently, the increasing incidence of cancer is propelling the expansion of the oncology precision medicine market.
How Is The Oncology Precision Medicine Market Examined Through Segment Analysis?
The oncology precision medicine market covered in this report is segmented –
1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs
2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies
3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types
4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications
5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays
2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)
3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)
4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies
5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies
6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers
Which Trends Are Expected To Shape The Oncology Precision Medicine Market?
Major companies within the oncology precision medicine market are concentrating on developing innovative solutions, including molecular tumor board programs, to aid multidisciplinary cooperation and enhance personalized treatment strategies. Molecular tumor boards are multidisciplinary teams of experts who review and interpret intricate genetic and molecular test results to suggest individualized cancer treatment plans. For instance, in April 2025, McKesson Corporation, a US-based healthcare services and information technology company, introduced the Precision Care Companion initiative aimed at supporting biomarker-driven cancer care by offering education, technological upgrades, and operational assistance to oncology practices. This extensive program unites physicians, clinical staff, business leaders, and pharmaceutical partners to foster a collaborative environment that accelerates the incorporation of advanced genomic testing and targeted therapies, ultimately assisting providers in delivering more personalized and effective cancer treatments while simultaneously improving patient outcomes.
Which Companies Form The Competitive Landscape Of The Oncology Precision Medicine Market?
Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.
Access The Complete Oncology Precision Medicine Market Report:
https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report
Which Region Accounts For The Highest Share Of The Oncology Precision Medicine Market?
North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Oncology Precision Medicine Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp
Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2026, By The Business Research Company
Precision Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model